ReviewWorld journal of gastrointestinal pharmacology and therapeutics2014
Prevention of hepatocellular carcinoma in patients with chronic hepatitis B.
Review in World journal of gastrointestinal pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Association between Hepatitis B Surface Antigen Levels and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection: Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2019Pooled it
- Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancerOncology letters · 2022Article
- Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate.F1000Research · 2022Article
- Effects of dexmedetomidine on perioperative stress response, inflammation and immune function in patients with different degrees of liver cirrhosis.Experimental and therapeutic medicine · 2018Article
- Review
- miR-106b targets DAB2 to promote hepatocellular carcinoma cell proliferation and metastasis.Oncology letters · 2018Article
- Clinical and Diagnostic Significance of Homer1 in hepatitis B virus-induced Hepatocellular Carcinoma.Journal of Cancer · 2018Article
- Study on the diagnosis of small hepatocellular carcinoma caused by hepatitis B cirrhosis via multi-slice spiral CT and MRI.Oncology letters · 2018Article
- miRNA-346 promotes proliferation, migration and invasion in liver cancer.Oncology letters · 2017Article
- Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.The American journal of gastroenterology · 2017Article
- Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.Annals of translational medicine · 2017Review
- Hepatitis B virus whole-X and X protein play distinct roles in HBV-related hepatocellular carcinoma progression.Journal of experimental & clinical cancer research : CR · 2016Article
- Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.World journal of gastroenterology · 2016Article
- Development and novel therapeutics in hepatocellular carcinoma: a review.Therapeutics and clinical risk management · 2016Review
- Expression of Yes-associated protein in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients.International journal of clinical and experimental medicine · 2015Article
- A genetic variant (rs17251221) in the calcium-sensing receptor relates to hepatocellular carcinoma susceptibility and clinical outcome treated by transcatheter hepatic arterial chemoembolization (TACE) therapy.Medical oncology (Northwood, London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic hepatitis B are at significant risk for hepatocellular carcinoma (HCC). Globally, over half a million people each year are diagnosed with HCC, with marked geographical variations. Despite overwhelming evidence for a causal role of hepatitis B virus (HBV) infection in the development of HCC and a well-established relationship between high baseline hepatitis B viral load and cumulative risk of HCC, the molecular basis for this association has not been fully elucidated. In addition, a beneficial role for antiviral therapy in preventing the development of HCC has been difficult to establish. This review examines the biological and molecular mechanisms of HBV-related hepatocarcinogenesis, recent results on the effect of modern nucleos(t)ides on the rate of HCC development in high risk HBV cohorts and the potential mechanisms by which long-term antiviral therapy with potent inhibitors of HBV replication might reduce the risk of HCC in patients with chronic hepatitis B. Although evidence from randomized controlled trials shows the favourable effects of antiviral agents in achieving profound and durable suppression of HBV DNA levels while improving liver function and histology, robust evidence of other long-term clinical outcomes, such as prevention of HCC, are limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.